R. A. Harrington

发表

Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

L. Wallentin, R. Harrington, H. Katus, 2013, JACC. Cardiovascular interventions.

Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials

V. Hasselblad, R. Califf, R. Giugliano, 2011, Circulation. Cardiovascular quality and outcomes.

Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

D. Ardissino, L. Wallentin, H. Katus, 2010, Circulation.

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial

C. Held, K. Mahaffey, A. Siegbahn, 2014 .

Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

M. Keltai, B. Lewis, C. Cannon, 2010 .

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

R. Harrington, R. A. Harrington, 1997, The American journal of cardiology.

TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING CORONARY ARTERY BY-PASS SURGERY: RESULTS FROM THE PLATO TRIAL

C. Held, C. Cannon, K. Mahaffey, 2010 .

Coronary Heart Disease Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

M. Keltai, A. Budaj, L. Wallentin, 2010 .

Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.

R. Califf, E. Topol, J. Deckers, 2000, American heart journal.

Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"

Justin T. Newcomer, N. Neerchal, J. Granett, 2008 .

Pharmacodynamics and Pharmacokinetics of Eptifibatide in Patients With Acute Coronary Syndromes: Prospective Analysis From PURSUIT

A. Lincoff, R. Harrington, N. Kleiman, 2001, Circulation.

Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.

R. Harrington, R. A. Harrington, 1999, American heart journal.

Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis

D. Ardissino, L. Wallentin, H. Katus, 2010, Circulation.

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation

L. Newby, P. Armstrong, F. Van de Werf, 2008, Heart.

Prognostic importance of physical examination for heart failure in non-St-elevation acute coronary syndromes the enduring value of Killip classification

U. Khot, Monica B. Khot, A. Lincoff, 2004 .

Clinical ResearchInterventional CardiologyUse of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial

E. Topol, A. Lincoff, H. Gurm, 2005 .

Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.

R. Califf, E. Topol, P. Armstrong, 2000, Circulation.

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot

V. Hasselblad, R. Becker, J. Alexander, 2004, Journal of thrombosis and haemostasis : JTH.

Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.

R. Califf, E. Topol, L. Newby, 2002, American heart journal.

Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.

K. Lee, R. Califf, E. Topol, 1994, Journal of the American College of Cardiology.

Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials.

C. O'connor, E. Topol, F. Van de Werf, 2003, American heart journal.